Nasdaq
RTTNews) – Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor darolutamide. The company is seeking approval for the use of darolutamide in combination with androgen deprivation therapy in patients with metas…
Read More
Bayer Submits Application To EMA For Third Indication Of Darolutamide
RTTNews
16:24
RTTNews) – Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor darolutamide. The company is seeking approval for the use of darolutamide in combination with androgen deprivation therapy in patients with metas…
